Hoth Therapeutics awarded key US patent for groundbreaking Alzheimer's treatment
- Hoth Therapeutics has been granted a U.S. patent for its Alzheimer's treatment, HT-ALZ.
- HT-ALZ targets the Substance P/Neurokinin-1 Receptor pathway, crucial in neuroinflammation.
- Preclinical studies show reduced neuroinflammation and improved cognitive functions.
- Formulation for clinical trials is underway, focusing on safety and efficacy in humans.
Read more
argenx highlights data showing patient impact across multiple immunology programs
- VYVGART and VYVGART Hytrulo show rapid, deep, and sustained responses in gMG and CIDP, with over 8,000 patient years of safety data.
- Real-world data indicates more than 50% of gMG patients reduced steroid use significantly after VYVGART initiation.
- argenx is expanding its neurology pipeline with empasiprubart advancing in MMN and ARGX-119 in ALS and CMS.
- A Phase 3 study of empasiprubart in MMN is planned to start by the end of 2024.
Read more
Neurosurgeon Joseph Georges receives CNS 2024 Rosenblum-Mahaley Clinical Research Award
- Joseph Georges, P.I. for Diakonos Oncology's Phase 1 trial, awarded for best clinical paper at CNS 2024.
- The trial involves DOC1021, a dendritic cell vaccine for glioblastoma, showing 93% survival over 12 months in 15 patients.
- DOC1021 uses a unique double loading technology to initiate a cytotoxic TH1 immune response without genetic modification.
- Diakonos plans to advance DOC1021 into a Phase 2 trial later this year.
Read more
